Cantharidin

Cantharidin

SCHEMBL1805181

CC12C(=O)OC(=O)C1(C)C1CCC2O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 1.00
TP53 P04637 5/20 1.00
LMNA P02545 4/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
RAB9A P51151 4/20 1.00
CYP3A4 P08684 3/20 1.00
HIF1A Q16665 3/20 1.00
NPC1 O15118 3/20 1.00
NFKB1 P19838 3/20 1.00
THPO P40225 3/20 1.00
GMNN O75496 3/20 1.00
PMP22 Q01453 3/20 1.00
CYP1A2 P05177 2/20 1.00
MTOR P42345 2/20 1.00
BLM P54132 2/20 1.00
PPM1B O75688 2/20 1.00
PPP1CC P36873 2/20 1.00
TFPI2 P48307 2/20 1.00
PPP5C P53041 2/20 1.00
PPP1CA P62136 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cantharidin SCHEMBL152261 1.00 MAPK1 (1.00) MAPK1TP53LMNASMN1; SMN2RAB9A
Cantharidin SCHEMBL152262 1.00 MAPK1 (1.00) MAPK1TP53LMNASMN1; SMN2RAB9A
Cantharidin SCHEMBL14120808 1.00 MAPK1 (1.00) MAPK1TP53LMNASMN1; SMN2RAB9A
SCHEMBL20885000 0.84 MAPK1 (0.71) MAPK1TP53LMNASMN1; SMN2RAB9A
SCHEMBL24129015 0.81 MAPK1 (0.67) MAPK1TP53LMNASMN1; SMN2RAB9A
SCHEMBL19619602 0.81 MAPK1 (0.67) MAPK1TP53LMNASMN1; SMN2RAB9A
SCHEMBL20618517 0.78 MAPK1 (0.62) MAPK1TP53LMNASMN1; SMN2RAB9A
SCHEMBL23080410 0.75 TP53 (0.57) MAPK1TP53LMNASMN1; SMN2RAB9A
SCHEMBL3496407 0.74 MAPK1 (0.59) MAPK1TP53LMNASMN1; SMN2RAB9A
SCHEMBL14025795 0.73 MAPK1 (0.57) MAPK1TP53LMNASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119119374-A UV-cured high-temperature-resistant resin for thermal runaway protection material and application 武汉长盈鑫科技有限公司 2024-12-13 CN claimed
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US claimed
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP claimed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO claimed
EP-4339199-B1 SYNTHESIS OF CANTHARIDIN VERRICA PHARMACEUTICALS INC (US) 2026-05-20 EP disclosed
US-12522724-B2 Polymer, dispersion, and paint INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2026-01-13 US disclosed
CN-223347303-U Automatic power input switching circuit of server BMC 深圳算界先峰信息科技有限公司 2025-09-16 CN disclosed
CN-120059033-A Polymer and coating 财团法人工业技术研究院 2025-05-30 CN disclosed
US-20250171643-A1 POLYMER AND COATING MATERIAL INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2025-05-29 US disclosed
EP-4556561-A1 EXPRESSION OF BIOMOLECULES WITH IMPROVED PROMOTER AND TIR CysBio ApS (DK) 2025-05-21 EP disclosed
CN-114514340-B Differential contrast plating for advanced packaging applications 朗姆研究公司 2025-03-21 CN disclosed
US-12221452-B2 Synthesis of cantharidin VERRICA PHARMACEUTICALS INC. (US) 2025-02-11 US disclosed
US-20090124558-A1 COMPOSITIONS AND METHODS FOR TREATING NEURAL ANOXIA AND SPREADING DEPRESSION FLORIDA ATLANTIC UNIVERSITY (US) 2009-05-14 US disclosed
WO-2009046322-A2 COMPOSITIONS AND METHODS FOR TREATING NEURAL ANOXIA AND SPREADING DEPRESSION FLORIDA ATLANTIC UNIVERSITY (US) 2009-04-09 WO disclosed
US-20080004440-A1 SCAR TREATMENT USING PROTEIN PHOSPHATASE INHIBITORS BIOBOTANIC CORP. (US) 2008-01-03 US disclosed
US-20080004440-A1 SCAR TREATMENT USING PROTEIN PHOSPHATASE INHIBITORS BIOBOTANIC CORP. (US) 2008-01-03 US disclosed
US-20080004440-A1 SCAR TREATMENT USING PROTEIN PHOSPHATASE INHIBITORS BIOBOTANIC CORP. (US) 2008-01-03 US disclosed
WO-2007149543-A2 SCAR TREATMENT USING PROTEIN PHOSPHATASE INHIBITORS BIOBOTANIC CORP. (US) 2007-12-27 WO disclosed
WO-2007149543-A2 SCAR TREATMENT USING PROTEIN PHOSPHATASE INHIBITORS BIOBOTANIC CORP. (US) 2007-12-27 WO disclosed
US-20070184044-A1 Thermoprotective compositions of PKG pathway inhibitors and method of use thereof DAWSON-SCULLY KENNETH 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS PPP1R10, TASP1, PPP5C MAPK1 812/4885TP53 1847/4885LMNA 4332/4885
US-12221452-B2 Synthesis of cantharidin TYR, CMA1, DPM1 MAPK1 1592/4885TP53 3315/4885LMNA 4280/4885
US-20080004440-A1 SCAR TREATMENT USING PROTEIN PHOSPHATASE INHIBITORS PPP3CA, PTPA, PPP5C MAPK1 1502/4885TP53 1882/4885LMNA 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.